Heron Therapeutics (NASDAQ:HRTX – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at Needham & Company LLC in a report issued on Thursday, Benzinga reports. They presently have a $5.00 price objective on the biotechnology company’s stock. Needham & Company LLC’s price target would suggest a potential upside of 66.67% from the […]